As of March 31, 2008, Nouveau Life Pharmaceuticals, Inc. carries a market capitalization of 5.12M, placing it among publicly traded companies globally. Its enterprise value stands at 5.18M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 5.12M |
| Enterprise Value | 5.18M |
As of March 31, 2008, Nouveau Life Pharmaceuticals, Inc. has 30.11M shares outstanding.
| Shares Outstanding | 30.11M |
These figures are as of March 31, 2008.
| PB Ratio | 119.92 |
| P/TBV Ratio | -13.51 |
| P/FCF Ratio | -225.43 |
| P/OCF Ratio | -237.83 |
As of March 31, 2008, Nouveau Life Pharmaceuticals, Inc. maintains a current ratio of 0.00, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities.
| Debt / Equity | 151.19 |
| Debt / EBITDA | -0.27 |
Over the twelve months ended March 31, 2008, Nouveau Life Pharmaceuticals, Inc. posted a negative return on equity (ROE) of -219.52, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -39.31, reflecting losses generated across the asset base.
| Return on Equity (ROE) | -219.52 |
| Return on Assets (ROA) | -39.31 |
These figures cover the twelve months ended March 31, 2008. EBITDA reached -235,593.00, while operating income came in at -503,315.00.
| Operating Income | -503,315.00 |
| Net Income | -503,315.00 |
| EBITDA | -235,593.00 |
| EBIT | -503,315.00 |
| Earnings Per Share (EPS) | -0.02 |
As of March 31, 2008, Nouveau Life Pharmaceuticals, Inc. holds 347.00 in cash and equivalents against 64,536.00 in total debt, resulting in a net debt position of 64,189.00. Total book value stands at 42,685.00, with working capital of -899,219.00 providing operational flexibility.
| Cash & Cash Equivalents | 347.00 |
| Total Debt | 64,536.00 |
| Net Debt | 64,189.00 |
| Equity (Book Value) | 42,685.00 |
| Working Capital | -899,219.00 |
Nouveau Life Pharmaceuticals, Inc. produced -21,516.00 in operating cash flow over the twelve months ended March 31, 2008. After subtracting -1,184.00 in capital expenditures, free cash flow totaled -22,700.00 - equivalent to 0.00 per share.
| Operating Cash Flow | -21,516.00 |
| Capital Expenditures | -1,184.00 |
| Free Cash Flow | -22,700.00 |
These figures cover the twelve months ended March 31, 2008. Free cash flow yield is negative at -0.44: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.32, meaning Nouveau Life Pharmaceuticals, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -0.32 |
| FCF Yield | -0.44 |